Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis
Authors
Keywords
Bevacizumab, Colorectal neoplasms, Erlotinib hydrochloride, Maintenance chemotherapy, Meta-analysis
Journal
International Journal of Clinical Pharmacy
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-04
DOI
10.1007/s11096-018-0754-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer
- (2017) Finn Ole Larsen et al. ONCOLOGY
- Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
- (2017) C. J. Punt et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series
- (2017) F. Di Fiore et al. JOURNAL OF CLINICAL ONCOLOGY
- Method to estimate relative risk using exposed proportion and case group data
- (2017) Yoichi Yada Scientific Reports
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model
- (2016) Chenbo Ding et al. BMC CANCER
- Maintenance strategy in metastatic colorectal cancer: A systematic review
- (2016) Ece Esin et al. CANCER TREATMENT REVIEWS
- Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
- (2016) Alexander Stein et al. Clinical Colorectal Cancer
- Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
- (2016) Wei Xu et al. CLINICAL DRUG INVESTIGATION
- Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis
- (2016) Giovanni Brandi WORLD JOURNAL OF GASTROENTEROLOGY
- PD-010 * Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in CRC models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial
- (2015) P. Mesange et al. ANNALS OF ONCOLOGY
- A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
- (2015) H. Hagman et al. ANNALS OF ONCOLOGY
- The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
- (2015) M. Ozcelik et al. Clinical & Translational Oncology
- Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
- (2015) Christophe Tournigand et al. LANCET ONCOLOGY
- Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2015) Fariba Ahmadizar et al. PLoS One
- Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
- (2014) Andy Hin-Fung Tsang WORLD JOURNAL OF GASTROENTEROLOGY
- A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
- (2013) A. Johnsson et al. ANNALS OF ONCOLOGY
- Interpretation of Odds and Risk Ratios
- (2013) A.M. O'Connor JOURNAL OF VETERINARY INTERNAL MEDICINE
- Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer
- (2011) Wells A. Messersmith et al. Clinical Colorectal Cancer
- Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma
- (2009) N. Schicher et al. CLINICAL CANCER RESEARCH
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
- (2009) N. A. Pennell et al. ONCOLOGIST
- Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
- (2008) A Bozec et al. BRITISH JOURNAL OF CANCER
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started